Company Directory > CRO > Jubilant Biosys Limited
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Jubilant Biosys Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Jubilant Biosys is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end drug discovery and development services. The company specializes in small molecule drug discovery, offering integrated services from target validation and hit identification to preclinical candidate selection, as well as GMP scale-up and API manufacturing. Operating as a subsidiary of Jubilant Pharmova Limited, the company leverages a global footprint with R&D centers in India (Bengaluru, Noida, Greater Noida) and France. It serves global pharmaceutical and biotech companies through flexible business models, focusing on therapeutic areas such as oncology, CNS, metabolic disorders, and pain & inflammation.
CLASSIFICATION
Company Type:CRO
Industry:CRO
Sub-Industry:Drug Discovery & Development
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$50M-$100M
Founded:2000
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical
Modalities:Small molecule, mAb, ADC, Oligonucleotides, Peptides
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Jubilant Pharmova Limited
Key Partnerships:Yale University (Small molecule discovery), Turning Point Therapeutics (Oncology research)
COMPETITION
Position:Leader
Competitors:Syngene International, Evotec, Charles River Laboratories, WuXi AppTec
LEADERSHIP
Key Executives:
Giuliano Perfetti - CEO & Managing Director
Benny Thomas - VP & CFO
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Jubilant Biosys Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.